Registered title, quoted from ClinicalTrials.gov
A Study of Combination Therapy in Patients With Resectable Liver Cancer
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Guangdong Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07684040, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
4. CNLC stage Ib, IIa, IIb, or IIIa HCC (excluding patients with main portal vein tumor thrombus).
Inclusion criterion 4
7. Child-Pugh class A liver function.
Inclusion criterion 7
6. No prior systemic treatment for HCC, including chemotherapy, targeted therapy, or immunotherapy.
Inclusion criterion 6
10. For patients with active HBV infection, effective antiviral therapy is required, with HBV DNA ≤2000 IU/mL or a ≥10-fold reduction after antiviral treatment.
Inclusion criterion 14
3. Planned or prior organ transplantation or allogeneic bone marrow transplantation.
Exclusion criterion 3
8. ECOG performance status 0-1.
Inclusion criterion 8
ANC ≥1.5 × 10\^9/L; Platelet count ≥75 × 10\^9/L; Hemoglobin ≥90 g/L.
Inclusion criterion 10
Albumin ≥30 g/L; Total bilirubin ≤1.5 × ULN; ALT, AST, and ALP ≤5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance >50 mL/min.
Inclusion criterion 11
1. Intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular carcinoma, fibrolamellar carcinoma, or any other active malignancy within the past 5 years (except HCC).
Exclusion criterion 1
11. Women of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 6 months after study completion. Male participants must also use effective contraception during the study and for 6 months after study completion.
Inclusion criterion 15
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07684040, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1. Voluntarily signed written informed consent.
- 2. Age ≥18 years; male or female.
- 3. Histologically, cytologically, or clinically confirmed hepatocellular carcinoma (HCC) according to EASL/AASLD criteria.
- 4. CNLC stage Ib, IIa, IIb, or IIIa HCC (excluding patients with main portal vein tumor thrombus).
- 5. Presence of vascular invasion and no extrahepatic metastasis, including PVTT (Vp1-Vp3), HVTT, or IVCTT.
- 6. No prior systemic treatment for HCC, including chemotherapy, targeted therapy, or immunotherapy.
- 7. Child-Pugh class A liver function.
- 8. ECOG performance status 0-1.
- 9. Adequate organ function:
- ANC ≥1.5 × 10\^9/L; Platelet count ≥75 × 10\^9/L; Hemoglobin ≥90 g/L.
- Albumin ≥30 g/L; Total bilirubin ≤1.5 × ULN; ALT, AST, and ALP ≤5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance >50 mL/min.
- INR ≤2.3 or PT prolongation ≤6 seconds.
- Urine protein <2+; if ≥2+, 24-hour urine protein <1.0 g.
- 10. For patients with active HBV infection, effective antiviral therapy is required, with HBV DNA ≤2000 IU/mL or a ≥10-fold reduction after antiviral treatment.
- 11. Women of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 6 months after study completion. Male participants must also use effective contraception during the study and for 6 months after study completion.
Exclusion Criteria:
- 1. Intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular carcinoma, fibrolamellar carcinoma, or any other active malignancy within the past 5 years (except HCC).
- 2. Severe allergy to iodinated contrast agents that prevents HAIC treatment.
- 3. Planned or prior organ transplantation or allogeneic bone marrow transplantation.
- 4. Treatment with another investigational drug within 28 days before study treatment.
- 5. Current or prior central nervous system metastases.
- 6. History of hepatic encephalopathy.
- 7. Current interstitial pneumonitis or interstitial lung disease.
- 8. Active autoimmune disease or history of autoimmune disease with risk of recurrence.
- 9. Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes within 14 days before study treatment.
- 10. Severe infection within 4 weeks before study treatment.
- 11. Gastrointestinal bleeding within 6 months before study treatment or a known risk of gastrointestinal bleeding.
- 12. Known hereditary or acquired bleeding disorders or thrombotic tendency.
- 13. Uncontrolled clinically significant cardiac disease or symptoms.
- 14. Moderate or severe ascites requiring therapeutic drainage or paracentesis.
- 15. Major vascular disease within 6 months before study treatment.
- 16. Inability to swallow oral medication, malabsorption syndrome, or any condition affecting gastrointestinal absorption.
- 17. Known hypersensitivity to any study drug, its excipients, monoclonal antibodies, or anti-angiogenic agents.
- 18. Any other serious acute or chronic medical condition, psychiatric disorder, or laboratory abnormality that may increase study risk, interfere with study results, or make the patient unsuitable for participation.
Quoted from ClinicalTrials.gov, NCT07684040, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07684040, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.